310 related articles for article (PubMed ID: 19857966)
1. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
[TBL] [Abstract][Full Text] [Related]
2. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors.
Wang T; Ioannidis S; Almeida L; Block MH; Davies AM; Lamb ML; Scott DA; Su M; Zhang HJ; Alimzhanov M; Bebernitz G; Bell K; Zinda M
Bioorg Med Chem Lett; 2011 May; 21(10):2958-61. PubMed ID: 21493067
[TBL] [Abstract][Full Text] [Related]
4. A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors.
Wang T; Ledeboer MW; Duffy JP; Salituro FG; Pierce AC; Zuccola HJ; Block E; Shlyakter D; Hogan JK; Bennani YL
Bioorg Med Chem Lett; 2010 Jan; 20(1):153-6. PubMed ID: 19945871
[TBL] [Abstract][Full Text] [Related]
5. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase.
Rosen MD; Woods CR; Goldberg SD; Hack MD; Bounds AD; Yang Y; Wagaman PC; Phuong VK; Ameriks AP; Barrett TD; Kanelakis KC; Chuang JC; Shankley NP; Rabinowitz MH
Bioorg Med Chem Lett; 2009 Dec; 19(23):6548-51. PubMed ID: 19854648
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ
Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959
[TBL] [Abstract][Full Text] [Related]
8. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.
Pissot-Soldermann C; Gerspacher M; Furet P; Gaul C; Holzer P; McCarthy C; Radimerski T; Regnier CH; Baffert F; Drueckes P; Tavares GA; Vangrevelinghe E; Blasco F; Ottaviani G; Ossola F; Scesa J; Reetz J
Bioorg Med Chem Lett; 2010 Apr; 20(8):2609-13. PubMed ID: 20231096
[TBL] [Abstract][Full Text] [Related]
9. 2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.
Gerspacher M; Furet P; Pissot-Soldermann C; Gaul C; Holzer P; Vangrevelinghe E; Lang M; Erdmann D; Radimerski T; Regnier CH; Chene P; De Pover A; Hofmann F; Baffert F; Buhl T; Aichholz R; Blasco F; Endres R; Trappe J; Drueckes P
Bioorg Med Chem Lett; 2010 Mar; 20(5):1724-7. PubMed ID: 20138510
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS.
Burns CJ; Harte MF; Bu X; Fantino E; Giarrusso M; Joffe M; Kurek M; Legge FS; Razzino P; Su S; Treutlein H; Wan SS; Zeng J; Wilks AF
Bioorg Med Chem Lett; 2009 Feb; 19(4):1206-9. PubMed ID: 19128971
[TBL] [Abstract][Full Text] [Related]
11. Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors.
Ioannidis S; Lamb ML; Almeida L; Guan H; Peng B; Bebernitz G; Bell K; Alimzhanov M; Zinda M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1669-73. PubMed ID: 20144546
[TBL] [Abstract][Full Text] [Related]
12. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target.
Guan H; Lamb ML; Peng B; Huang S; Degrace N; Read J; Hussain S; Wu J; Rivard C; Alimzhanov M; Bebernitz G; Bell K; Ye M; Zinda M; Ioannidis S
Bioorg Med Chem Lett; 2013 May; 23(10):3105-10. PubMed ID: 23562594
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.
Hanan EJ; van Abbema A; Barrett K; Blair WS; Blaney J; Chang C; Eigenbrot C; Flynn S; Gibbons P; Hurley CA; Kenny JR; Kulagowski J; Lee L; Magnuson SR; Morris C; Murray J; Pastor RM; Rawson T; Siu M; Ultsch M; Zhou A; Sampath D; Lyssikatos JP
J Med Chem; 2012 Nov; 55(22):10090-107. PubMed ID: 23061660
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
[TBL] [Abstract][Full Text] [Related]
16. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
Milkiewicz KL; Weinberg LR; Albom MS; Angeles TS; Cheng M; Ghose AK; Roemmele RC; Theroff JP; Underiner TL; Zificsak CA; Dorsey BD
Bioorg Med Chem; 2010 Jun; 18(12):4351-62. PubMed ID: 20483621
[TBL] [Abstract][Full Text] [Related]
18. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
[TBL] [Abstract][Full Text] [Related]
19. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
Wang T; Lamb ML; Scott DA; Wang H; Block MH; Lyne PD; Lee JW; Davies AM; Zhang HJ; Zhu Y; Gu F; Han Y; Wang B; Mohr PJ; Kaus RJ; Josey JA; Hoffmann E; Thress K; Macintyre T; Wang H; Omer CA; Yu D
J Med Chem; 2008 Aug; 51(15):4672-84. PubMed ID: 18646745
[TBL] [Abstract][Full Text] [Related]
20. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
